Critical Review: Abeona Therapeutics (ABEO) & ChromaDex (CDXC)

Abeona Therapeutics (NASDAQ: ABEO) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Abeona Therapeutics and ChromaDex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abeona Therapeutics -2,946.58% -27.69% -25.32%
ChromaDex -21.89% -47.30% -32.25%

Valuation & Earnings

This table compares Abeona Therapeutics and ChromaDex’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $890,000.00 869.90 -$21.87 million ($0.66) -25.08
ChromaDex $26.81 million 11.85 -$2.92 million ($0.14) -47.07

ChromaDex has higher revenue and earnings than Abeona Therapeutics. ChromaDex is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Abeona Therapeutics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Institutional & Insider Ownership

42.0% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 6.8% of ChromaDex shares are held by institutional investors. 6.8% of Abeona Therapeutics shares are held by company insiders. Comparatively, 11.6% of ChromaDex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abeona Therapeutics and ChromaDex, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics 0 0 9 0 3.00
ChromaDex 0 0 3 0 3.00

Abeona Therapeutics presently has a consensus price target of $27.00, suggesting a potential upside of 63.14%. ChromaDex has a consensus price target of $7.00, suggesting a potential upside of 6.22%. Given Abeona Therapeutics’ higher possible upside, research analysts plainly believe Abeona Therapeutics is more favorable than ChromaDex.

Summary

Abeona Therapeutics beats ChromaDex on 7 of the 12 factors compared between the two stocks.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

ChromaDex Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply